Altimmune Inc
ALT
Company Profile
Business description
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Contact
910 Clopper Road
Suite 201S
GaithersburgMD20878
USAT: +1 240 654-1450
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
59
Stocks News & Analysis
stocks
Looking for growth outside the ASX100
Small caps have outperformed blue chips this year. Here’s some opportunities outside the ASX100.
stocks
Netflix and Warner Bros. Discovery: Surprisingly high merger price alters shareholder value for both
Our view on the blockbuster merger.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,915.00 | 26.10 | 0.29% |
| CAC 40 | 8,088.70 | 26.04 | -0.32% |
| DAX 40 | 24,006.83 | 21.31 | -0.09% |
| Dow JONES (US) | 47,729.92 | 225.07 | -0.47% |
| FTSE 100 | 9,632.66 | 34.35 | -0.36% |
| HKSE | 25,765.36 | 319.72 | -1.23% |
| NASDAQ | 23,511.12 | 67.01 | -0.28% |
| Nikkei 225 | 50,581.94 | 90.07 | 0.18% |
| NZX 50 Index | 13,486.32 | 2.33 | 0.02% |
| S&P 500 | 6,842.29 | 28.11 | -0.41% |
| S&P/ASX 200 | 8,624.40 | 28.80 | 0.34% |
| SSE Composite Index | 3,924.08 | 21.27 | 0.55% |